Literature DB >> 6989170

Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.

J Pedersen-Bjergaard, M M Hansen, C H Geisler, N I Nissen.   

Abstract

Prednimustine, a chlorambucil ester of prednisolone, was administered to 16 patients with non-Hodgkin lymphomata (NHL) and 14 patients with chronic lymphocytic leukaemia (CLL), all previously treated with steroids and alkylating agents. Response was obtained in 8 patients with NHL and 11 patients with CLL. Two NHL patients had long-lasting complete remissions. Median duration of response for lymphomata was 12 weeks, for CLL more than 15 weeks. Delayed reversible and rather pronounced myelosuppression was the major side-effect observed in median 6 weeks from the start of Prednimustine with a median duration of 4 weeks.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6989170     DOI： 10.1111/j.0954-6820.1980.tb09708.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN： 0001-6101


  9 in total

1.  Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).

Authors:  M Freund; S Wunsch-Zeddies; M Schäfers; J Wysk; I Seidel; W Hiddemann; A R Hanauske; H Link; H J Schmoll; H Poliwoda
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

2.  Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

Authors:  H Ehrsson; I Wallin; S O Nilsson; B Johansson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  [Clinical relevance of glucocorticoid receptors in the treatment of lymphoid neoplasias].

Authors:  U Gehring; A D Ho
Journal:  Klin Wochenschr       Date:  1987-03-16

4.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Authors:  K E Landys
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

6.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.

Authors:  B Lönnqvist; B Andersson; M Björkholm; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; H Mellstedt; J Palmblad; C Paul; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.

Authors:  D R Gandara; C B George; C A Ries; M M Koretz; J P Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Authors:  D R Gandara; C A Ries; S A Schiff; C B George; J P Lewis; M M Koretz; S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.